HOME / ¹®¼°øÀ¯ / ¸®Æ÷Æ®/³í¹® / ÀǾàÇÐ
0
0°ÇÀÇ Èı⺸±âÀÚ°¡¸é¿ª°ú À̽ĸ鿪ÀÇ °³³ä¿¡ ´ëÇØ ±â¼úÇÑ ¸®Æ÷Æ® Âü°íÀÚ·áÀÔ´Ï´Ù.
4.ÀÚ°¡ ¸é¿ªÁúȯÀÇ Ä¡·á
Áõ»ó¿ÏÈ°¡ ¸ñÀû
¸²ÇÁ±¸ÀÇ Áõ½ÄÀ» ´ÊÃß±â À§ÇØ ¸é¿ª¾ïÁ¦Á¦(corticosteroid, azathioprine, cyclophosphamide µî) Åõ¿©
È°¼ºÈµÈ t¼¼Æ÷¸¸ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦ ; cyclosporin a, fk-506
¿°Áõ¹ÝÀÀÀÇ Á¦¾î-tnf-¥á ÀúÇØÁ¦
È°¼ºÈµÈ t ¼¼Æ÷ÀÇ Á¦¾î-il-2¼ö¿ëüÀÇ ¥á¾Æ´ÜÀ§¿¡ ´ëÇÑ ´ÜŬ·ÐÇ×ü
¸é¿ª°ü¿ëÀÇ À¯µµ-±¸°À» ÅëÇÑ Àå±âÀûÀÎ Ç׿ø Åõ¿©
e.g., mbp ±¸°Åõ¿©·Î msȯÀÚÀÇ mbp¹ÝÀÀ t¸²ÇÁ±¸ °¨¼Ò
ÀÚ°¡¸é¿ª (autoimmunity)
-normal immune response against pathogen
-autoimmune response against self antigen
elimination, memory lymphocytes chronic immune response
positive feedback loop of inflammation
1) ubiquitous autoantigen
e.g., Àü½ÅÈ«¹Ý·çǪ½º ÀÚ°¡¸é¿ª (autoimmunity)
5.ÀÚ°¡¸é¿ªÁúȯÀÇ ¸¸¼ºÈ ±âÀü
2) epitope spreading
e.g., Àü½ÅÈ«¹Ý·çǪ½º self destructive process leads to other self antigens that were not initially targets at the onset of autoimmunity become target at later stages
ÀÚ°¡¸é¿ª (autoimmunity) À̽ĸ鿪 (transplantation immunology) À̽Ä(transplantation)
: ÇÑ °³Ã¼·ÎºÎÅÍ ¼¼Æ÷, Á¶Á÷, ±â°ü µî°ú °°Àº À̽ÄÆí(graft)À» ´Ù¸¥ °³Ã¼·Î ¿Å±â´Â °Í
°ø¿©ÀÚ, donor ¼ö¿ëÀÚ; recipient (¼÷ÁÖ; host) µ¿¼ÒÀ̽Ä(orthotropic transplantation) : À̽ÄÆíÀÌ ÇغÎÇÐÀûÀ¸·Î Á¤»óÀûÀÎ À§Ä¡¿¡ ÀÌ½Ä À̼ÒÀ̽Ä(heterotropic transplantation) : À̽ÄÆíÀÌ ÇغÎÇÐÀûÀ¸·Î ´Ù¸¥ À§Ä¡¿¡ ÀÌ½Ä ¼öÇ÷(transfusion) : Ç÷¾×¼¼Æ÷ ¶Ç´Â Ç÷ÀåÀ» À̽Ä
ÀÚ°¡À̽ÄÆí(autologous graft, autograft) : ÀÚ±â Àڽſ¡°Ô À̽ÄÇÏ´Â À̽ÄÆí
µ¿°èÀ̽ÄÆí(syngeneic graft, syngraft)
: À¯ÀüÀûÀ¸·Î µ¿ÀÏÇÑ µÎ °³Ã¼°£¿¡ À̽ÄÇÏ´Â À̽ÄÆí
µ¿Á¾À̽ÄÆí(allogeneic graft, allograft)
: °°Àº Á¾ ³»¿¡¼ À¯ÀüÀûÀ¸·Î ´Ù¸¥ µÎ °³Ã¼°£¿¡ À̽ÄÇÏ´Â À̽ÄÆí
µ¿Á¾Ç׿ø(alloantigen); µ¿Á¾À̽ÄÆí¿¡¼ Ç׿øÀ¸·Î ÀνĵǴ ºÐÀÚ
ÀÌÁ¾À̽ÄÆí(xenogeneic graft, xenograft) (ÀÌÇÏ »ý·«)
¹ÞÀº º°Á¡
0/5
0°³ÀÇ º°Á¡
¹®¼°øÀ¯ ÀڷḦ µî·ÏÇØ ÁÖ¼¼¿ä.
¹®¼°øÀ¯ Æ÷ÀÎÆ®¿Í Çö±ÝÀ» µå¸³´Ï´Ù.
Æ÷ÀÎÆ® : ÀÚ·á 1°Ç´ç ÃÖ´ë 5,000P Áö±Þ
Çö±Ý : ÀÚ·á 1°Ç´ç ÃÖ´ë 2,000¿ø Áö±Þ